Sale Of Pfizer’s Established Products Not Off The Table, Exec Says
This article was originally published in PharmAsia News
Pfizer CFO Frank D’Amelio talks about the big pharma’s long-term vision and cost-reduction initiatives during the Morgan Stanley Healthcare conference. Management will continue reviewing the portfolio on an ongoing basis to see how best to maximize shareholder value, he said.
You may also be interested in...
Pfizer begins the process to split off its animal health business with an IPO in an effort to save on taxes and refrain from diluting the current shareholder base.